A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models

Although WNT signaling is frequently dysregulated in solid tumors, drugging this pathway has been challenging due to off-tumor effects. Current clinical pan-WNT inhibitors are nonspecific and lead to adverse effects, highlighting the urgent need for more specific WNT pathway–targeting strategies. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Do, Myan, Wu, Christina C.N., Sonavane, Pooja R., Juarez, Edwin F., Adams, Stephen R., Ross, Jason, Rodriguez y Baena, Alessandra, Patel, Charmi, Mesirov, Jill P., Carson, Dennis A., Advani, Sunil J., Willert, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742765/
https://www.ncbi.nlm.nih.gov/pubmed/34667113
http://dx.doi.org/10.1158/1535-7163.MCT-21-0548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742765/
https://www.ncbi.nlm.nih.gov/pubmed/34667113
http://dx.doi.org/10.1158/1535-7163.MCT-21-0548

Ejemplares similares